Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Shanghai Fosun Pharmaceutical (Group) Co ( (HK:2196) ) has provided an update.
Shanghai Fosun Pharmaceutical has renewed its Financial Services Agreement with Fosun Finance for three years starting January 2026. This agreement, which involves deposit and financial services, is deemed a continuing connected transaction under Hong Kong Listing Rules, requiring reporting and shareholder approval due to its scale. The company has established an Independent Board Committee and appointed an independent financial adviser to guide shareholders on the agreement.
The most recent analyst rating on (HK:2196) stock is a Hold with a HK$17.20 price target. To see the full list of analyst forecasts on Shanghai Fosun Pharmaceutical (Group) Co stock, see the HK:2196 Stock Forecast page.
More about Shanghai Fosun Pharmaceutical (Group) Co
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a joint stock limited company incorporated in China, operating within the pharmaceutical industry. The company is involved in the development, manufacturing, and sale of pharmaceutical products, with a focus on healthcare services and medical devices.
Average Trading Volume: 10,877,098
Technical Sentiment Signal: Hold
Current Market Cap: HK$79.26B
For an in-depth examination of 2196 stock, go to TipRanks’ Overview page.